MacroGenics reports 2022 net loss of $119.8M; cash runway extended through 2025 via $250M non-dilutive funding

MACROGENICS INC

Net loss $119.8M ($1.95/share) vs $202.1M in 2021; revenue $151.9M (up 96% YoY).
Cash $154.3M at Dec 2022; plus $100M from DRI royalty sale; runway through 2025.
TAMARACK trial modified: removed control arm; clinical update expected in 2024.
Lorigerlimab mCRPC data: 28.6% PSA50, 25.7% confirmed partial responses.
TZIELD approval milestone: two $15M payments received; two due by Sept 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MACROGENICS INC reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 15, 2023, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the year ended December 31, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

MACROGENICS INC filing history →

Source: SEC EDGAR

accession 0001125345-23-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.